Daiichi Sankyo is at the forefront of innovative cancer treatment technologies, particularly through its development of antibody-drug conjugates (ADCs). One of the most notable products is ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2-directed ADC that has garnered significant recognition, including the prestigious 2024 Prix Galien USA Award for Best Biotechnology Product. This therapy utilizes Daiichi Sankyo's proprietary DXd ADC technology, which combines a HER2 monoclonal antibody with a topoisomerase I inhibitor payload linked via cleavable linkers. ENHERTU is designed to target and treat various HER2-positive cancers, including breast cancer and non-small cell lung cancer, and is approved in over 65 countries, showcasing its global impact on cancer treatment.

In addition to ENHERTU, Daiichi Sankyo is advancing its ADC portfolio with several investigational therapies, including datopotamab deruxtecan, which targets TROP2, and other ADCs directed at different cancer markers. The company is committed to ongoing clinical research to explore the efficacy and safety of these treatments across multiple cancer types. Furthermore, Daiichi Sankyo's TURALIO (pexidartinib) represents another significant advancement, being the first oral systemic therapy approved for tenosynovial giant cell tumor (TGCT), a rare tumor that can severely impact patients' quality of life. This dedication to innovative therapies underscores Daiichi Sankyo's mission to transform cancer treatment and improve patient outcomes through cutting-edge science and technology.

United States

At Daiichi Sankyo, we create essential medicine for longer, better lives. By uniting cutting edge science and technology with a genuine interest in people, we develop high quality, life changing solutions for the patients of today and tomorrow with great care and unwavering dedication.
With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. 

For more information, please visit www.daiichisankyo.us.

See our community guidelines here: https://bit.ly/4fLkZS8


Daiichi Sankyo

Company Details